Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer
Cancer · 15.01.2023 · 129 (2) · 215-225
DOI: 10.1002/cncr.34533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 17.11.2022. Verfasst von Joris Mallard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France. Hauptthemen laut MEDLINE: Hand Strength, Breast Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Université de Strasbourg.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Fatigue is a hallmark of breast cancer and is associated with skeletal muscle deconditioning. If cancer‐related fatigue occurs early during chemotherapy (CT), the development of skeletal muscle deconditioning and its effect on exercise capacity remain unclear. The aim of this study was to investigate the evolution of skeletal muscle deconditioning and exercise capacity in patients with early‐stage breast cancer during CT.
Methods
Patients with breast cancer had a visit before undergoing CT, at 8 weeks, and at the end of chemotherapy (post‐CT). Body composition was determined through bioelectrical impedance analysis. Knee extensor, handgrip muscle force and fatigue was quantified by performing maximal voluntary isometric contractions and exercise capacity using the 6‐min walking test. Questionnaires were also administered to evaluate quality of life, cancer‐related fatigue, and physical activity level.
Results
Among the 100 patients, reductions were found in muscle mass (−2.3%, p = .002), exercise capacity (−6.7%, p < .001), and knee extensor force (−4.9%, p < .001) post‐CT, which occurred within the first 8 weeks of treatment with no further decrease thereafter. If muscle fatigue did not change, handgrip muscle force decreased post‐CT only (−2.5%, p = .001), and exercise capacity continued to decrease between 8 weeks and post‐CT (−4.6%, p < .001). Quality of life and cancer‐related fatigue were impaired after 8 weeks ( p < .001) and remained stable thereafter, whereas the physical activity level remained stable during chemotherapy.
Conclusions
Similar to cancer‐related fatigue, skeletal muscle deconditioning and reduced exercise capacity occurred early during breast cancer CT. Thus, it appears essential to prevent these alterations through exercise training implemented during CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France.
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France.
ORCID-Profile: Allan F Pagano
Förderung
- Université de Strasbourg
Zitieren
APA
Mallard, J., Hucteau, E., Schott, R., Trensz, P., Pflumio, C., Kalish-Weindling, M., Favret, F., Pivot, X., Hureau, T. J., & Pagano, A. F. (2023). Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer. Cancer, 129(2), 215-225. https://doi.org/10.1002/cncr.34533
Vancouver
Mallard J, Hucteau E, Schott R, Trensz P, Pflumio C, Kalish-Weindling M, et al. Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer. Cancer. 2023;129(2):215-225. doi:10.1002/cncr.34533
BibTeX
@article{Mallard2023,
author = {Mallard, Joris and Hucteau, Elyse and Schott, Roland and Trensz, Philippe and Pflumio, Carole and Kalish-Weindling, Michal and Favret, Fabrice and Pivot, Xavier and Hureau, Thomas J and Pagano, Allan F},
title = {Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer},
journal = {Cancer},
year = {2023},
volume = {129},
number = {2},
pages = {215--225},
doi = {10.1002/cncr.34533}
}
EUVIMED